The Nasdaq is a stock exchange market that was asked to create a by-product by the National Association of Securities Dealers back in the year 2000 in order to form a public company that was available to everyone and anyone can access it. Because of the dot – com bubble, the value of the NASDAQ Composite Index fell down in the year 2000 which was on the rise during the 1990s when the dot – com bubble did not exist. It rose again in March 2000 and reached 5,132.52 but again fell in April 2000 to 3,227.
What is ABUS stock?
NASDAQ: ABUS stock at https://www.webull.com/quote/nasdaq-abus stands for Arbutus Biopharma Corporation Common Stock is basically a market on which investors spend their money in order to earn a profit. The rate of the ABUS market is $2.40 according to the latest report submitted on 17th of July, 2020. The Nasdaq stock exchange market is looking out for the ABUS market to be turned as strong in the IPO market in this summertime. The sector of ABUS market is Health Care which is using Major Pharmaceutical as an industry. The share volume of ABUS is 3,518,172 and its Average Volume Label is 1,331,771 and also its previous close is $2.01 which turns out to be a profit.
The yearly based which 52 weeks high and low of ABUS market is $3.66/$0.82respectively and if one considers its market cap then it will give you the result as 165,507,348 and has 1 BETA. It works under the exchange program of Nasdaq – Gs and is one of the top stocks, the investors would be compelled to invest in. It is located in Parkway of Burnaby in Canada and it has set a target to achieve in a year as such $4.50. The forward P/E for the ABUS for at least one year is -2.31 and its Earning per Share which is also known as the EPS is around $-2.67.
The Arbutus Biopharma Corporation Common Stock worked really hard to expand their business by trading in other fields also. Eventually, it made its place in the global platform and is one of the known markets for the stock exchange.
There are so many important people running this company as such the Chief Financial & Accounting Officer is David C. Hastings and the Chief Business Officer is Michael J. McLaughlin. Michael J. Sofia is working in the ABUS company as Chief Scientific Officer. Last but not the least William H. Collier is holding the position of the Chief executive Officer and Director and also President of the ABUS company. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.